单位:[1]Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China华中科技大学同济医学院附属协和医院内科学系心血管内科[2]Department of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA[3]Clinical Center for Human Genomic Research, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China华中科技大学同济医学院附属协和医院[4]Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA[5]Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA[6]Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China华中科技大学同济医学院附属同济医院心脏大血管外科胸外科外科学系外科学系[7]Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA[8]Critical Illness Research, Lawson Health Research Institute, Ontario, Canada
Currently, most antioxidants do not show any favorable clinical outcomes in reducing myocardial ischemia-reperfusion (I/R) injury, suggesting an urgent need for exploring a new regulator of redox homeostasis in I/R hearts. Here, using heart-specific transgenic (TG) and knockdown (KD) mouse models, tumor susceptibility gene 101 (Tsg101) is defined as a novel cardiac-protector against I/R-triggered oxidative stress. RNA sequencing and bioinformatics data surprisingly reveal that most upregulated genes in Tsg101-TG hearts are transcribed by Nrf2. Accordingly, pharmacological inhibition of Nrf2 offsets Tsg101-elicited cardio-protection. Mechanistically, Tsg101 interacts with SQSTM1/p62 through its PRR domain, and promotes p62 aggregation, leading to recruitment of Keap1 for degradation by autophagosomes and release of Nrf2 to the nucleus. Furthermore, knockout of p62 abrogates Tsg101-induced cardio-protective effects during I/R. Hence, our findings uncover a previously unrecognized role of Tsg101 in the regulation of p62/Keap1/Nrf2 signaling cascades and provide a new strategy for the treatment of ischemic heart disease.
基金:
National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 GM-126061, GM-132149]; American Heart Association (AHA) Established Investigator AwardAmerican Heart Association [17EIA33400063]; AHA Pre-doctoral FellowshipAmerican Heart Association [18PRE34030123]
第一作者单位:[1]Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China[2]Department of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA[3]Clinical Center for Human Genomic Research, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, China
共同第一作者:
通讯作者:
通讯机构:[2]Department of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA
推荐引用方式(GB/T 7714):
Deng Shan,Essandoh Kobina,Wang Xiaohong,et al.Tsg101 positively regulates P62-Keap1-Nrf2 pathway to protect hearts against oxidative damage[J].REDOX BIOLOGY.2020,32:doi:10.1016/j.redox.2020.101453.
APA:
Deng, Shan,Essandoh, Kobina,Wang, Xiaohong,Li, Yutian,Huang, Wei...&Fan, Guo-Chang.(2020).Tsg101 positively regulates P62-Keap1-Nrf2 pathway to protect hearts against oxidative damage.REDOX BIOLOGY,32,
MLA:
Deng, Shan,et al."Tsg101 positively regulates P62-Keap1-Nrf2 pathway to protect hearts against oxidative damage".REDOX BIOLOGY 32.(2020)